Charles Schwab Investment Management Inc Puma Biotechnology, Inc. Transaction History
Charles Schwab Investment Management Inc
- $601 Billion
- Q3 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 125,372 shares of PBYI stock, worth $620,591. This represents 0.0% of its overall portfolio holdings.
Number of Shares
125,372
Previous 127,443
1.63%
Holding current value
$620,591
Previous $437,000
47.14%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding PBYI
# of Institutions
139Shares Held
35.4MCall Options Held
264KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.4 Million11.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.69MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.15MShares$10.6 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA2.05MShares$10.2 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $226M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...